In the past few years, different therapeutical approaches have been performed to modulate the amyloid brain depositions in APP-transgenic mice, including restricted administration of pharmaceutical agents [20], rich cholesterol diet [21], caloric diet [22], and intensive exercise [23]; however, Aβ-based immunotherapy has been shown to be the most promising research field in reducing amyloid loads [24–28] and reversing memory deficits [9, 10, 29] in AD mouse models. Here, APP is linked to Alzheimer disease.